A detailed history of Quadrant Capital Group LLC transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Quadrant Capital Group LLC holds 878 shares of ABUS stock, worth $2,739. This represents 0.0% of its overall portfolio holdings.

Number of Shares
878
Previous 277 216.97%
Holding current value
$2,739
Previous $0 Infinity%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.26 - $2.92 $1,358 - $1,754
601 Added 216.97%
878 $2,000
Q4 2023

Feb 08, 2024

SELL
$1.69 - $2.54 $1,073 - $1,612
-635 Reduced 69.63%
277 $0
Q3 2023

Nov 14, 2023

BUY
$1.9 - $2.27 $1,732 - $2,070
912 New
912 $1,000
Q4 2022

Feb 10, 2023

SELL
$1.91 - $2.85 $9,924 - $14,808
-5,196 Reduced 96.2%
205 $0
Q3 2022

Nov 10, 2022

BUY
$1.88 - $2.88 $10,153 - $15,554
5,401 New
5,401 $10,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $468M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.